pancreatic cancer

CellMax is developing and applying its CTC platform for early detection of colorectal cancer and more long term for breast and prostate cancer.

 

The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.

Investigators published an initial report on the method, which they call cfMeDIP-Seq, last week, and are now hoping to move to analysis of samples from longitudinal health studies.

The approach, called cfMeDIP-seq, could distinguish early-stage pancreatic cancer from healthy controls and differentiate several types of cancer.

The approach allows scientists to look at single amino acid variants linked to diseases like cancer and could aid the investigation of tumor heterogeneity.

The company is developing a blood-based liquid biopsy test based on the method to monitor 5-hydroxymethylcytosine levels in cell-free tumor DNA.  

The company also published a study describing ImmRay PanCan-D biomarker signature that it said could be used to detect early-stage pancreatic cancer.

The University of North Carolina at Chapel Hill's technology is based on set of patient-cell derived gene signatures for classifying four pancreatic subtypes.

One of the variants leads to increased phosphorylation of a signaling pathway as well as to increased cell proliferation, hinting at how it contributes to disease risk.

A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.

Pages

New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.

Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.

In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.